6233 RESULTS
CONFERENCE COVERAGE 2024-11-22 Conference Coverage Most Alzheimerologists agree that lecanemab and donanemab are a start, but insufficient to treat this disease. At the Clinical Trials in Alzheimer’s Disease conference, held last month in Madrid, scientists not only debated how to make
CONFERENCE COVERAGE 2024-11-21 Conference Coverage Yes, blood tests for Alzheimer’s disease are ready for prime time. So pronounced Suzanne Schindler, Washington University, St. Louis, in a keynote presentation at CTAD 2024 last month in Madrid. In answering a question that has been ra
RESEARCH NEWS 2024-11-20 Research News Despite higher rates of clinically diagnosed dementia among people from non-white racial and ethnic groups, historically they have been underrepresented in AD clinical trials. Efforts are underway to boost recruitment among these populations
RESEARCH NEWS 2024-11-19 Research News To keep patients on amyloid immunotherapy safe, doctors need to be able to spot subtle signs of ARIA on MRI scans. For memory clinics that have limited experience with these therapies, this may prove challenging. Now those clinics can consid
CONFERENCE COVERAGE 2024-11-15 Conference Coverage Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October 29-November 1 in Madrid, speakers upda
CONFERENCE COVERAGE 2024-11-14 Conference Coverage While anti-tau antibodies are beginning to look promising (see previous story), small molecules that modify tau proteins haven’t yet fared well in clinical trials. At the 16th Clinical Trials on Alzheimer’s Disease conference, held Oct
CONFERENCE COVERAGE 2024-11-14 Conference Coverage The fifth time may be the charm for antibodies targeting tau. At the 16th Clinical Trials on Alzheimer’s Disease conference, held October 29 to November 1 in Madrid, Brussels-based UCB Pharma presented the first signal that a monoclona
CONFERENCE COVERAGE 2024-11-14 Conference Coverage Lecanemab has been in clinical use in the U.S. for nearly two years, and in Japan for not quite a year. How is it going? At the Clinical Trials on Alzheimer’s Disease conference, held October 29 through November 1 in Madrid, Spain, spe
CONFERENCE COVERAGE 2024-11-08 Conference Coverage Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease conference, held October 29-Nov
CONFERENCE COVERAGE 2024-11-08 Conference Coverage Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of hazardous brain bleeding, reflected i
RESEARCH NEWS 2024-11-08 Research News In recent years, CryoEM has enabled scientists to decipher the structures of the fibrils that form various deposits in neurodegenerative disease. They have not only solved disease-specific folding structures for fibrils of Aβ, tau, TDP-43, T
COMMUNITY NEWS 2024-11-08 Community News Scientists in industry and academia were shocked and saddened to hear of the sudden passing of Bruce Albala. Albala died in Greece on October 16 while celebrating his 40th wedding anniversary with his wife. “The AD community, and especially
RESEARCH NEWS 2024-10-31 Research News TMEM106b’s rap sheet is growing. Some of its genetic variants are linked to both Alzheimer’s disease and frontotemporal dementia, and fibrils of this lysosomal protein accumulate in several neurodegenerative diseases. Now, in an October 18 p
RESEARCH NEWS 2024-10-30 Research News Scientists broadly agree that both apolipoprotein E and microglia are necessary ingredients for amyloidosis. In mice devoid of ApoE, or of their microglia, scant plaques form. Now, a sweeping study published October 9 in Immunity unveils a m
RESEARCH NEWS 2024-10-29 Research News Far from a static barrier, the brain’s extensive interface with the blood is increasingly being appreciated as an active border, one that serves not only to keep some proteins out, but to let others in (Oct 2024 conference news). Once across
